Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 9/09/21 → 31/12/24 |
Keywords
- Lymphoma
- B-cell Malignancies
- Haematological malignancy
- Clinical trial
Clinical Trial Phase
- Phase I
A Phase 1a/1b Dose Escalation and Dose Expansion, First-in-human, Open-Labeled Study of the Safety,Pharmacokinetics, and Pharmacodynamics of ETH-155008, A Dual Inhibitor of CDK4/6 and Pim, in Subjects with Relapsed or Refractory B-cell NHL, CLL/SLL and AML
- Patil, Sushrut (Primary Chief Investigator (PCI))
- Kennedy, Nola (Project Manager)
Project: Research